Abstract 237P
Background
The purpose of this paper is to report the dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity-modulated radiotherapy to ipsilateral neck only. In unilaterally treated neck, the thyroid lobe present contralaterally is passively spared. We compared the effects of consciously sparing it and associated dosimetric results and their statistical significance.
Methods
Treatment plans of 38 buccal mucosa cancer patients, treated to ipsilateral side only, receiving same dose and fractionation to buccal mucosa & elective neck irradiation were evaluated. Since October 2021 we adopted a department protocol of conscious sparing of contralateral thyroid in unilaterally treated head and neck cancer patients. 19 of these had conscious sparing of contralateral thyroid (group A) whereas 19 of old plans were evaluated when C/L thyroid were not given constraints & are being passively spared due to location on contralateral/non treatment side of neck (group B). Treatment planning was done using 7 beam (6 MV) IMRT in Eclipse 13.7 TPS in all of these patients. The best treatment plans were selected ensuring 95% PTV dose coverage and acceptable dose to organs at risk (OARs). Uniform contouring, plan optimization and evaluation protocols were followed for all of these patients.
Results
The mean dose of thyroid in group A was 10.23Gy whereas in group B it was 19.35Gy which is statistically significant (P value – 0.0001). The mean thyroid volume in group A was 4.76cc and in group B was 5.86cc which is not significant statistically different from group B, thyroid dose. Table: 237P
Groups | No. | Mean ± SD | ‘t’ value | P value |
Thyroid dose with constraint | 19 | 10.23 ± 2.18 | 9.004, df=36 | 0.0001* |
Thyroid dose without constraint | 19 | 19.35 ± 3.84 |
Unpaired ‘t’ test applied. P value = 0.0001, Significant
Conclusions
Unilateral treatment of neck passively reduces dose to OARs present on the contralateral side. This study emphasizes that conscious sparing of contralateral thyroid lobe can further reduce the dose to significant levels. This reduction can preserve thyroid function further. Larger clinical trials are required to corroborate this dosimetric gain with clinical thyroid function preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
265P - Tumor-agonistic genomic profiling
Presenter: Naomi Hayashi
Session: Poster viewing 03
266P - Dynamic mutation profiles of Chinese patients with EGFR T790M advanced NSCLC receiving osimertinib
Presenter: Xuchao Zhang
Session: Poster viewing 03
267P - Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Presenter: Amit Rauthan
Session: Poster viewing 03
269P - MET alterations in EGFR mutated NSCLC: A lesser known evil
Presenter: Mansi Sharma
Session: Poster viewing 03
271P - Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Presenter: Kaushik R
Session: Poster viewing 03